Patents by Inventor Samuel Broder

Samuel Broder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pharmaceutical composition containing 2-amino-6-chloropurine-9-.beta.-D-2',3'-dideoxyribofuranoxside
    Patent number: 5580860
    Abstract: An anti-AIDS virus agent is disclosed, which is characterized in that it contains the 2',3'-dideoxypurinenucleosides represented by the chemical formula (I): ##STR1## as an effective ingredient.
    Type: Grant
    Filed: December 5, 1989
    Date of Patent: December 3, 1996
    Assignee: Sanyo Kokusaku Pulp Co., Ltd.
    Inventors: Eiji Kojima, Hidetoshi Yoshioka, Kunichika Murakami, Hiroaki Mitsuya, Takuma Shirasaka, Samuel Broder
  • Treatment of retroviral induced dementia by administration of 2',3'-dideoxyinosine
    Patent number: 5376642
    Abstract: A preferred method and dosages for treatment of retrovirus-induced dementia by the administration of 2',3'-dideoxyinosine(ddI) is disclosed.
    Type: Grant
    Filed: March 1, 1993
    Date of Patent: December 27, 1994
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert Yarchoan, Hiroaki Mitsuya, Samuel Broder
  • Method of treating HIV with 2',3'-dideoxyinosine
    Patent number: 5254539
    Abstract: A method for tearing retroviral infections including acquired immune deficiency syndrome (AIDS) with 2',3'-dideoxyinosine or 2',3'-dideoxyadenosine is disclosed. This antiviral effect is irreversible with 2',3'-dideoxyinosine and 2',3'-dideoxyadenosine but reversible with 2',3'-dideoxyguanosine.
    Type: Grant
    Filed: February 28, 1991
    Date of Patent: October 19, 1993
    Assignee: U.S. Government, Dept. of Health and Human Services, c/o National Institutes of Health
    Inventors: Hiroaki Mitsuya, Samuel Broder
  • Therapeutic application of dideoxycytidinene
    Patent number: 5116822
    Abstract: The compound 2',3'-dideoxycytidinene has an antiviral effect against human immunodeficiency virus (HIV) and may therefore be used as a therapeutic agent for treating AIDS and related diseases.
    Type: Grant
    Filed: July 2, 1990
    Date of Patent: May 26, 1992
    Assignees: Stichting Rega VZW, The United States of America as represented by the Department of Health and Human Serices
    Inventors: Erik D. A. De Clercq, Piet A. M. M. Herdewijn, Samuel Broder, Jan M. R. Balzarini
  • Treatment of human retroviral infections with 2',3'-dideoxyinosine alone and in combination with other antiviral compounds
    Patent number: 5026687
    Abstract: A preferred method and dosages for the short and long-term treatment of human retroviral infections, or retroviral-like infections, including acquired immunodeficiency syndrome (AIDS) and other manifestations of human immunodeficiency virus (HIV) infection, with 2',3'-dideoxyinosine (ddl) are disclosed, along with a protocol for halting and restarting 2',3'-dideoxyinosine to minimize certain side effects.
    Type: Grant
    Filed: January 3, 1990
    Date of Patent: June 25, 1991
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Robert Yarchoan, Hiroaki Mitsuya, Samuel Broder
  • Therapeutic application of dideoxycytidinene
    Patent number: 4963533
    Abstract: The present invention relates to a composition containing the compound 2', 3'-dideoxycytidinene which has an antiviral effect against human immunodeficiency virus (HIV) and may therefore be used as a therapeutic agent for the treatment of AIDS and AIDS related diseases.
    Type: Grant
    Filed: October 24, 1986
    Date of Patent: October 16, 1990
    Assignees: Stichting Rega VZW (REGA), The Government of the United States of America
    Inventors: Erik D. A. de Clercq, Piet A. M. M. Herdewijn, Samuel Broder, Jan M. R. Balzarini
  • Pyrimidine and purine 1,2-butadiene-4-ols as anti-retroviral agents
    Patent number: 4935427
    Abstract: Compounds which are active against retroviruses have the following formulaHOH.sub.2 C--CH.dbd.C.dbd.CH--Bwherein B is a purine or pyrimidine heterocyclic ring which is preferably selected from the group consisting of cytosine, 5-halo substituted cytosine, 5-alkyl substituted cytosine, 6-aminopurine, 2,6-diaminopurine, 6-hydroxypurine, 2-amino-6-hydroxypurine, 3-deazapurines, 7-deazapurines, 8-azapurines, and 6-azapyrimidines.
    Type: Grant
    Filed: December 31, 1987
    Date of Patent: June 19, 1990
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Samuel Broder, Seiji Hayashi, Hiroaki Mitsuya, Jiri Zemlicka, Shashikant Phadtare
  • Antiviral compositions and methods
    Patent number: 4879277
    Abstract: Compositions containing 2',3'-dideoxycytidine and its triphosphates for use in treating retroviral infections including acquired immune deficiency syndrome (AIDS) are disclosed with preferred methods of treatment which provide protection against cytophatic effects of human immunodeficiency virus (HIV).
    Type: Grant
    Filed: August 11, 1987
    Date of Patent: November 7, 1989
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Hiroaki Mitsuya, Samuel Broder
  • Antiviral compositions and methods
    Patent number: 4861759
    Abstract: Compositions containing 2',3'-dideoxyadenosine, 2',3'-dideoxyinosine, and dideoxyguanosine and their triphosphates for use in treating retroviral infections including acquired immune deficiency syndrome (AIDS) are disclosed with preferred methods of treatment which provide protection against cytopathic effects of human immunodeficiency virus (HIV).
    Type: Grant
    Filed: August 11, 1987
    Date of Patent: August 29, 1989
    Assignee: The United States of America as represented by the Department of Health and Human Services
    Inventors: Hiroaki Mitsuya, Samuel Broder
  • Cell line producing human monoclonal antibody which binds to HTLV-I producing cells
    Patent number: 4722888
    Abstract: The present invention is an immortalized B-cell line which produces a human monoclonal antibody IgG-Kk which specifically binds to the envelope antigen of human T-cell leukemia virus Type 1 (HTLV-I). This monoclonal antibody is useful as a diagnostic reagent by binding to the antigen specifically expressed on the surface of HTLV producing cells. Furthermore, this monoclonal antibody is useful as a therapeutic reagent, in combination with complement, for the lysis of HTLV-1 producing cells.
    Type: Grant
    Filed: March 29, 1985
    Date of Patent: February 2, 1988
    Assignee: United States of America as represented by the Department of Health and Human Services
    Inventors: Samuel Broder, Shuzo Matsushita, Marjorie Robert-Guroff
  • Immortalized T-lymphocyte cell line for testing HTLV-III inactivation
    Patent number: 4704357
    Abstract: This invention is an immortalized T-cell clone, designated ATH8, which is highly sensitive to the cytopathic effect of HTLV-III. The ATH8 T-cell clone is used in mass screening systems to rapidly and easily determine the in vitro capacity of new drugs or other agents to inactivate or inhibit HTLV-III or related cytopathic retroviruses.
    Type: Grant
    Filed: September 30, 1985
    Date of Patent: November 3, 1987
    Assignee: United States of America as represented by the Department of Health and Human Services
    Inventors: Hiroaki Mitsuya, Samuel Broder
  • Anti-retroviral compounds
    Patent number: RE33887
    Abstract: A-B-C wherein A and C are each independently 2',3'dideoxynucleosides and B is a linking group; and a method of treating or preventing a retroviral injection in a subject by administering the compounds of the invention.
    Type: Grant
    Filed: November 2, 1990
    Date of Patent: April 14, 1992
    Assignees: Hoffmann-La Roche Inc., United States of America
    Inventors: Steve Tam, Manfred Weigele, Samuel Broder, Hiroaki Mitsuya